Update in Hematology
Authors: Scott H. Goodnight
Journal: Annals of Internal Medicine (1998)

Updates1 April 1998Update in HematologyScott H. Goodnight, MD and Donald I. Feinstein, MDScott H. Goodnight, MDFrom Oregon Health Sciences University, Portland, Oregon; and University of Southern California School of Medicine, Los Angeles, California.Search for more papers by this author and Donald I. Feinstein, MDFrom Oregon Health Sciences University, Portland, Oregon; and University of Southern California School of Medicine, Los Angeles, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-7-199804010-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Recent advances in hematology have focused on thromboembolic diseases and common anemias. Home-based delivery of low-molecular-weight heparin has become more common, and we have gained insight into the natural history of and risks for spontaneous venous thromboembolic disease. Pernicious anemia, previously believed to be more common in men, was found more often in women with previously undiagnosed disease. Iron deficiency in young women may be associated with poor school performance, even before anemia develops. Finally, major relief has been found for patients with multiple myeloma and bone pain.Thromboembolic DiseaseThe major advance seen in thromboembolic disease in the past ...References1. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996; 334:682-7. Google Scholar2. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997; 337:663-9. Google Scholar3. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med. 1997; 337:657-62. Google Scholar4. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997; 157:289-94. Google Scholar5. Mannuci PM, Tripodi A. Mechanisms, markers and management of hypercoagulable states. Haemostasis. 1996; 26(Suppl 4):1-8. Google Scholar6. Macik BG, Ortel TL. Clinical and laboratory evaluation of the hypercoagulable states. Clin Chest Med. 1995; 16:375-87. Google Scholar7. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1997; 127:895-903. Google Scholar8. Hall WJ. Update in geriatrics. Ann Intern Med. 1997; 127:557-64. Google Scholar9. Grisso JA. Update in women's health. Ann Intern Med. 1997; 127:1006-12. Google Scholar10. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed). 1986; 292:526. Google Scholar11. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Spelzer FE, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996; 348:983-7. Google Scholar12. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996; 348:981-3. Google Scholar13. Vandenbroucke JP, Helmerhorst FM. Risk of venous thrombosis with hormone-replacement therapy. Lancet. 1996; 348:972. Google Scholar14. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997; 336:393-8. Google Scholar15. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized, controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996; 14:2552-9. Google Scholar16. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335:1785-91. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Oregon Health Sciences University, Portland, Oregon; and University of Southern California School of Medicine, Los Angeles, California.Corresponding Author: Scott H. Goodnight, MD, Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road, L-471, Portland, OR 97201-3098.Current Author Addresses: Dr. Goodnight: Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road, L-471, Portland, OR 97201-3098. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByOutpatient treatment of deep vein thrombosis: translating clinical trials into practice 1 April 1998Volume 128, Issue 7Page: 545-551KeywordsDeep vein thrombosisFolic acidHeparinHormone replacement therapyIron deficiencyLow molecular weight heparinMedical risk factorsMultiple myelomaPernicious anemiaVenous thromboembolism Issue Published: 1 April 1998 CopyrightCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...